First Human Trial of COVID-19 Drug Set to Begin
Researchers at the pharmaceutical giant Eli Lilly announced yesterday that it will start a trial on a new drug designed specifically for COVID-19, a milestone in the race to stop the infectious disease, according to STAT News.
The early-stage trial is the world's first for an antibody treatment that specifically targets the novel coronavirus. Eli Lilly is one of the several drugmakers and research institutions working on vaccines, antivirals and other treatments to help people infected with the virus that has already killed over 370,000 worldwide, as Reuters reported.
The treatment that Eli Lilly will test uses an antibody that was developed using a blood sample from one of the first U.S. patients to recover from coronavirus. As The Hill noted, antibody treatments that are developed specifically to fight COVID-19 show promise as effective treatments. The drug remdesivir, which has been touted as a potential treatment, already existed and was repurposed to help patients with COVID-19. In trials so far, it has shown moderate results as it slightly shortened the time that patients were infected.
The first phase of the trial will test if the therapy is safe and well-tolerated with results expected later this month. The first COVID-19 patients to receive the new drug are hospitalized at New York University's Grossman School of Medicine in New York, Cedars-Sinai in Los Angeles, and Emory University in Atlanta, Eli Lilly told CNN.
The trial will test for side effects and is only being tested in 32 people at the various sites.
The company said that if the trial shows the medicine is effective against COVID-19, it may be fast tracked through the regulatory process and be available by the autumn, as CNN reported.
"Until now, scientists have been trying to repurpose medicines, drugs, that were designed for new diseases to see if they work in COVID-19, but as soon as this epidemic started, we got to work making a new medicine against this disease," said Dr. Dan Skovronsky, Eli Lilly's senior vice president and chief scientific officer, as CNN reported. "Now we're ready and testing it in patients."
While Indianapolis-based Eli Lilly is developing the drug, the medicine was actually discovered by a Vancouver company, AbCellera. Other companies are also working on developing an antibody drug, too. Biotech firm Regeneron expects to begin a test soon as does a partnership of Vir Biotechnology and GlaxoSmithKline, according to STAT News.
"We're not racing against each other," said Skovronsky of the other companies, as STAT News reported. "We're racing against the death toll from the virus. I hope there will be multiple successful [antibody drugs]. I expect there will be."
Regeneron Pharmaceuticals has said it plans to start clinical studies in June to test its antibody cocktail treatment and is aiming to have hundreds of thousands of preventative doses available by the end of August, according to Reuters.
Lilly's treatment is designed to block it from locking on to human cells, thus neutralizing the virus, as Reuters reported.
Scientists at AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases selected the specific antibodies they thought would be most potent. Then Lilly scientists engineered the treatment, known as a monoclonal antibody therapy. Monoclonal antibodies have an approach has worked to treat other illnesses. There are monoclonal antibody therapies that treat HIV, asthma, lupus, Ebola and some forms of cancer, as CNN reported.
"Ultimately, what we would hope is that this would be an effective treatment that would provide very strongly neutralizing antibodies to lower the virus and help patients recover," said Mark Mulligan, the director of the vaccine center at New York University Langone Health, who is one of the doctors working in the study that Lilly is funding, as STAT News reported.
"It feels it feels like we're making history," said Skovronsky, according to STAT News. Just three months after Covid-19 became a global pandemic, the pharmaceutical industry has been able to confront it, he said. "This has got to be a new phase in the fight."
- Dogs Can Smell COVID-19 - EcoWatch ›
- Drugs Touted by Trump for COVID-19 Increase Heart Risks, Studies ... ›
- Coronavirus Vaccine Candidate Shows Promise in Mice - EcoWatch ›
- In 'Major Breakthrough,' Oxford Researchers Say Cheap, Available Steroid Can Save Lives From Coronavirus - EcoWatch ›
- 3 Vaccine Trials Show Promise Against Coronavirus - EcoWatch ›
- Steroids Can Save the Lives of Severely Ill COVID Patients, Several Trials Confirm - EcoWatch ›
People across New England witnessed a dramatic celestial event Sunday night.
EcoWatch Daily Newsletter
By David Reichmuth
Over the last month, I've seen a number of opinion articles attacking electric vehicles (EVs). Sadly, this comes as no surprise: now that the Biden administration is introducing federal policies to accelerate the roll out of electric vehicles, we were bound to see a reaction from those that oppose reducing climate changing emissions and petroleum use.
The majority of EVs sold in 2020 were models with a starting price (Manufacturers Suggested Retail Price) under $40,000 and only a fifth of models had a starting price over $60,000.
On Friday, China set out an economic blueprint for the next five years, which was expected to substantiate the goal set out last fall by President Xi Jinping for the country to reach net-zero emissions before 2060 and hit peak emissions by 2030.
The Great Trail in Canada is recognized as the world's longest recreational trail for hiking, biking, and cross-country skiing. Created by the Trans Canada Trail (TCT) and various partners, The Great Trail consists of a series of smaller, interconnected routes that stretch from St. John's to Vancouver and even into the Yukon and Northwest Territories. It took nearly 25 years to connect the 27,000 kilometers of greenway in ways that were safe and accessible to hikers. Now, thanks to a new partnership with the Canadian Paralympic Committee and AccessNow, the TCT is increasing accessibility throughout The Great Trail for people with disabilities.
Trans Canada Trail and AccessNow partnership for AccessOutdoors / Trails for All project. Mapping day at Stanley Park Seawall in Vancouver, British Columbia with Richard Peter. Alexa Fernando<p>This partnership also comes at a time when access to outdoor recreation is more important to Canadian citizens than ever. <a href="https://www150.statcan.gc.ca/n1/daily-quotidien/200527/dq200527b-eng.htm" target="_blank" rel="noopener noreferrer">Studies from the spring of 2020</a> indicate that Canadian's <a href="https://www.bnnbloomberg.ca/moneytalk-mental-health-during-covid-19-1.1567633" target="_blank" rel="noopener noreferrer">mental health has worsened</a> since the onset of social distancing protocols due to COVID-19. </p><p>The <a href="https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/safe-activities-during-covid19/art-20489385" target="_blank" rel="noopener noreferrer">Mayo Clinic</a> lists hiking, biking, and skiing as safe activities during COVID-19. Their website explains, "When you're outside, fresh air is constantly moving, dispersing these droplets. So you're less likely to breathe in enough of the respiratory droplets containing the virus that causes COVID-19 to become infected."</p><p>TCT leadership took this into consideration when embarking on the accessibility project. McMahon explains that there has never been a more important time to bring accessibility to the great outdoors: "Canadians have told us that during these difficult times, they value access to natural spaces to stay active, take care of their mental health, and socially connect with others while respecting physical distancing and public health directives. This partnership is incredibly important especially now as trails have become a lifeline for Canadians."</p><p>Together, these organizations are paving the way for better physical and mental health among all Canadians. To learn more about the TCT's mission and initiatives, check out their <a href="https://thegreattrail.ca/stories/" target="_blank">trail stories</a> and <a href="https://thegreattrail.ca/wp-content/uploads/2021/01/TCT_2020-Donor-Impact-Report_EN_8.5x14-web.pdf" target="_blank">2020 Impact Report</a>.</p>